KD Logo

Recent Insider Activity Suggests Potential Gains for Zymeworks BC Inc (ZYME)

Zymeworks BC Inc’s filing revealed that its Chair & CEO Galbraith Kenneth unloaded Company’s shares for reported $63996.0 on Jan 08 ’24. In the deal valued at $11.22 per share,5,706 shares were sold. As a result of this transaction, Galbraith Kenneth now holds 23,762 shares worth roughly $0.21 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Moore Paul Andrew sold 2,339 shares, generating $26,233 in total proceeds. Upon selling the shares at $11.22, the Chief Scientific Officer now owns 7,367 shares.

Before that, Astle Christopher sold 1,431 shares. Zymeworks BC Inc shares valued at $16,050 were divested by the SVP & Chief Financial Officer at a price of $11.22 per share. As a result of the transaction, Astle Christopher now holds 6,503 shares, worth roughly $58331.91.

A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in early January has reiterated a ‘”a Neutral”‘ rating for it. Jefferies also remained covering ZYME and has increased its forecast on December 20, 2022 with a “Buy” recommendation from previously “Hold” rating. H.C. Wainwright revised its rating on November 01, 2022. It rated ZYME as “a Neutral” which previously was an “a Buy”.

Price Performance Review of ZYME

On Monday, Zymeworks BC Inc [NASDAQ:ZYME] saw its stock fall -1.10% to $8.97. Over the last five days, the stock has gained 6.41%. Zymeworks BC Inc shares have fallen nearly -13.67% since the year began. Nevertheless, the stocks have risen 2.75% over the past one year. While a 52-week high of $13.14 was reached on 02/27/24, a 52-week low of $6.01 was recorded on 04/26/24. SMA at 50 days reached $8.95, while 200 days put it at $9.04. A total of 0.91 million shares were traded, compared to the trading of 0.33 million shares in the previous session.

Levels Of Support And Resistance For ZYME Stock

The 24-hour chart illustrates a support level at 8.81, which if violated will result in even more drops to 8.65. On the upside, there is a resistance level at 9.13. A further resistance level may holdings at 9.29. The Relative Strength Index (RSI) on the 14-day chart is 51.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 35.29%. Stochastics %K at 69.71% indicates the stock is a holding.

Most Popular